Van Hulzen Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Van Hulzen Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-400	Closed	-$7.34K	–	319
2024 Q4	$7.34K	Sell	400 -99,381	-100%	-$1.6M	﹤0.01%	813
2024 Q3	$1.53M	Buy	99,781 +8,296	+9%	+$138K	0.11%	134
2024 Q2	$1.49M	Buy	91,485 +14,231	+18%	+$230K	0.1%	134
2024 Q1	$1.43M	Sell	77,254 -1,396	-2%	-$34.6K	0.09%	139
2023 Q4	$2.46M	Buy	78,650 +25,580	+48%	+$611K	0.17%	94
2023 Q3	$1.11M	Buy	53,070 +24,180	+84%	+$657K	0.09%	144
2023 Q2	$692K	Sell	28,890 -760	-3%	-$16.9K	0.06%	148
2023 Q1	$558K	Buy	+29,650	New	+$565K	0.05%	167

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Van Hulzen Asset Management's ACAD Position: Q1 2025 in Review

Van Hulzen Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 400 shares — an estimated $7.34K sold.

Van Hulzen Asset Management first reported a position in ACAD in Q1 2023 and held it in 8 quarters. The position peaked at $2.46M in Q4 2023. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

Van Hulzen Asset Management reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Van Hulzen Asset Management sold 400 Acadia Pharmaceuticals shares in Q1 2025, an estimated $7.34K.
Van Hulzen Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2023 and held it in 8 quarters.
Van Hulzen Asset Management's Acadia Pharmaceuticals position peaked at $2.46M in Q4 2023.
320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Van Hulzen Asset Management's 13F filing for Q1 2025, filed 14 May 2025.